Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences

Rhea-AI Summary

Aeglea BioTherapeutics, Inc. (AGLE) will participate in upcoming investor conferences to present their pipeline of antibody therapeutics for inflammatory bowel disease. The conferences include Guggenheim 5th Annual Inflammation & Immunology Conference, Stifel 2023 Annual Healthcare Conference, and Jefferies 2023 London Healthcare Conference. Webcasts of the presentations can be accessed on the Aeglea website.

WALTHAM, Mass., Oct. 30, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will participate in the following investor conferences:

• Guggenheim 5^th Annual Inflammation & Immunology Conference, New York, New York – November 7^th, 2023
• Stifel 2023 Annual Healthcare Conference, New York, New York – November 14^th, 2023
• Jefferies 2023 London Healthcare Conference, London, UK – November 15-16^th, 2023

To access the webcast of Aeglea's presentations, please visit the "Events & Presentations" page within the Investors section of the Aeglea website at ir.aeglea.com.

About Aeglea BioTherapeutics
In June 2023, Aeglea completed its asset acquisition of Spyre and shifted its disease focus to IBD. Aeglea is advancing a pipeline of antibody therapeutics with the potential to transform the treatment of IBD.  Aeglea's approach combines novel antibody engineering, rational therapeutic combinations, and precision immunology with the goal of maximizing efficacy, safety, and convenience of treatments for IBD. The company is developing antibodies targeting α4β7, TL1A, and IL-23.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-to-participate-in-upcoming-november-investor-conferences-301972037.html

SOURCE Aeglea BioTherapeutics, Inc.

FAQ

What is the ticker symbol of Aeglea BioTherapeutics, Inc.?

The ticker symbol of Aeglea BioTherapeutics, Inc. is AGLE.

What is the focus of Aeglea's pipeline?

Aeglea's pipeline focuses on antibody therapeutics for inflammatory bowel disease.

Which investor conferences will Aeglea participate in?

Aeglea will participate in the Guggenheim 5th Annual Inflammation & Immunology Conference, Stifel 2023 Annual Healthcare Conference, and Jefferies 2023 London Healthcare Conference.

Where can I access the webcast of Aeglea's presentations?

The webcast of Aeglea's presentations can be accessed on the Aeglea website, specifically on the 'Events & Presentations' page within the Investors section.